




FIG. 2




FIG. 3




FIG. 4




FIG. 5




FIG. 6





FIG. 7






FIG. 8

FIG. 9




FIG. 10A




FIG. 10B




FIG. 11A





FIG. 11B






FIG. 13





FIG. 14






FIG. 15





FIG. 16

FIG. 17






FIG. 19A




FIG. 20A




FIG. 20B




FIG. 20C




FIG. 21A




FIG. 21B




FIG. 21D





FIG. 21C








FIG. 23C




FIG. 23B






FIG. 23A








FIG. 25A




FIG. 25B




FIG. 25C




FIG. 26A




FIG. 26B




FIG. 27B




FIG. 27A

Detected number of viral copies as a function of loaded virus




FIG. 28




FIG. 29A




FIG. 29B




FIG. 29C




FIG. 30A




FIG. 30B




FIG. 31B




FIG. 31A




FIG. 32B




FIG. 32A




FIG. 33B




FIG. 33A




FIG. 34A




FIG. 34B





FIG. 34C






FIG. 36B






FIG. 36A





Multimer:




FIG. 37B





FIG. 37C

FIG. 38






FIG. 39




FIG. 40






FIG. 42A



Group	Virus	MSP Injection Volume (ul)	MSP Dose (mg)	STARTERS	PBMCs
VEGF-C cryogel + Free Virus + MSP-STARTERS	1.1e^7	10	0.15	89.6	20e^6
VEGF-C cryogel + MSP-Virus + MSP-STARTERS	1.1e^7	20	0.3	89.6	20e^6
VEGF-C cryogel + PBS+ MSP-STARTERS ("PBS")	1.1e^7	10	0.15	89.6	20e^6
Blank cryogel + Free Virus + Blank MSPs ("Free virus control")	1.1e^7	10	0.15	0	20e^6
MSP Concentration: 15 mg/ml					

FIG. 42B





FIG. 43A






FIG. 44A





FIG. 44B



- Free virus + MSP-STARTERS + VEGF-C
- MSP-virus + MSP-STARTERS + VEGF-C
- ▼ Free virus control
- ◇ PBS

FIG. 45B







FIG. 45A

Group 1: Free virus + MSP-STARTERS + VEGF-C
Group 2: MSP-virus + MSP-STARTERS + VEGF-C
Group 3: Free virus control
Group 4: PBS

FIG. 46A





FIG. 46B



Group 1: Free virus + MSP-STARTERS + VEGF-C
Group 2: MSP-virus + MSP-STARTERS + VEGF-C
Group 3: Free virus control
Group 4: PBS





FIG. 47






FIG. 48A




FIG. 48B

Co-Stimulatory Binders	CD3 Binder	Name	
CD25	ANTI-CD3 (1)	F5 CD25	Alternative Costim
IL6Rb	ANTI-CD3 (1)	F5 IL6Rb	
CD27	ANTI-CD3 (1)	F5 CD27	
41BB	ANTI-CD3 (1)	F5 41BB	
ICOS	ANTI-CD3 (1)	F5 ICOS	
CD2	ANTI-CD3 (2)	F5 ANTI-CD3 (2)	Alternative CD3 Binder

FIG. 49A




FIG. 49B

Variants	ANTI-CD3 Arm	ANTI-Costim Arm
NEG2042	ANTI-CD3 (1)	CD2
NEG2043	ANTI-CD3 (1)	ANTI-CD28 (1)
NEG2044	ANTI-CD3 (1)	ANTI-CD28 (2)
NEG2050	ANTI-CD3 (2)	CD2
NEG2051	ANTI-CD3 (3)	CD2
NEG2052	ANTI-CD3 (2)	ANTI-CD28 (1)
NEG2053	ANTI-CD3 (3)	ANTI-CD28 (1)
F5-Not Fc Silenced	ANTI-CD3 (1)	CD2
Transact		CD28

Alternative
CD3 Binders

FIG. 50A




FIG. 50B






FIG. 51B

Day 1: CD25 MFI



Day 4: CAR+ %






FIG. 52B




FIG. 53A




FIG. 53B

	Alginate		VEGF-C		TMA		CD19 CAR	
	Cryogel	Laponite	Protein	MSPs	STARTERS	Virus		
Injectable 1	+	+	+	-	-	-		
Injectable 2	-	-	-	+	+	+		

FIG. 53C




FIG. 53D




FIG. 53H

T cells in circulation at D18




FIG. 53I

CARTs in circulation at D18




FIG. 53J

%CART of total T cells at D18




FIG. 53K




FIG. 53L




FIG. 54A




FIG. 54B




FIG. 54C

HA gel with 0.25 mg/ml laponite – in situ vs. particles




FIG. 54D

HA gel with 1 mg/ml laponite – in situ vs. particles




FIG. 55A




FIG. 55B

